CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) attributable to BioTime, Inc.	$ 49,288	$ (17,112)
Net loss allocable to non-controlling interest	(2,264)	(6,885)
Adjustments to reconcile net income (loss) attributable to BioTime, Inc. to net cash used in operating activities:
Gain on deconsolidation of OncoCyte (Note 3)	(71,697)	0
Unrealized loss on equity method investment in Asterias at fair value	26,097	0
Unrealized gain on equity method investment in OncoCyte at fair value	(16,142)	0
Depreciation expense, including amortization of leasehold improvements	216	429
Amortization of intangible assets	602	1,314
Stock-based compensation	1,026	3,373
Subsidiary shareholder expense for subsidiary warrants	0	3,125
Amortization of discount on related party convertible debt	253	65
Foreign currency remeasurement (gain) or loss and other	(829)	347
Deferred income tax provision	3,877	0
Deferred grant income	0	(243)
Changes in operating assets and liabilities:
Accounts and grants receivable, net	248	(36)
Receivables from affiliates, net of payables	231	0
Prepaid expenses and other current assets	338	(259)
Accounts payable and accrued liabilities	655	1,457
Other	3	112
Net cash used in operating activities	(8,098)	(14,313)
CASH FLOWS FROM INVESTING ACTIVITIES:
Deconsolidation of cash and cash equivalents of OncoCyte	(8,898)	0
Purchase of equipment and other assets	(205)	(583)
Restricted cash	0	(815)
Payments on construction in progress	0	(267)
Other	(51)	0
Cash used in investing activities	(9,154)	(1,665)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common shares	20,125	0
Fees paid on sale of common shares	(1,345)	0
Proceeds from exercises of stock options	25	49
Reimbursement from landlord on construction in progress	200	567
Repayment of capital lease obligation	(31)	(17)
Net proceeds from sale of common shares of subsidiary	0	165
Proceeds from issuance of related party convertible debt	123	0
Net cash provided by financing activities	19,097	764
Effect of exchange rate changes on cash and cash equivalents	(117)	117
NET CHANGE IN CASH AND CASH EQUIVALENTS:	1,728	(15,097)
CASH AND CASH EQUIVALENTS:
At beginning of the period	22,088	42,229
At end of the period	$ 23,816	$ 27,132